Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $178.64.

RGEN has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the period. Vanguard Group Inc. increased its position in shares of Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC raised its stake in Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. lifted its position in Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC grew its stake in Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after buying an additional 6,872 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 1.7 %

RGEN stock opened at $137.12 on Friday. The company has a market cap of $7.70 billion, a price-to-earnings ratio of -268.86, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen has a twelve month low of $113.50 and a twelve month high of $187.25. The business has a 50 day moving average price of $154.75 and a two-hundred day moving average price of $148.22. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.